- Home
- INAB vs MRKR Comparison
INAB vs MRKR Comparison
Compare INAB & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- MRKR
- Stock Information
- Founded
- INAB 2016
- MRKR N/A
- Country
- INAB United States
- MRKR United States
- Employees
- INAB N/A
- MRKR N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- MRKR Health Care
- Exchange
- INAB Nasdaq
- MRKR Nasdaq
- Market Cap
- INAB 10.6M
- MRKR 11.6M
- IPO Year
- INAB 2021
- MRKR N/A
- Fundamental
- Price
- INAB $2.08
- MRKR $1.04
- Analyst Decision
- INAB Strong Buy
- MRKR Strong Buy
- Analyst Count
- INAB 2
- MRKR 3
- Target Price
- INAB $108.00
- MRKR $13.17
- AVG Volume (30 Days)
- INAB 67.4K
- MRKR 285.6K
- Earning Date
- INAB 11-11-2025
- MRKR 11-13-2025
- Dividend Yield
- INAB N/A
- MRKR N/A
- EPS Growth
- INAB N/A
- MRKR N/A
- EPS
- INAB N/A
- MRKR N/A
- Revenue
- INAB N/A
- MRKR $5,388,071.00
- Revenue This Year
- INAB N/A
- MRKR N/A
- Revenue Next Year
- INAB N/A
- MRKR $9.06
- P/E Ratio
- INAB N/A
- MRKR N/A
- Revenue Growth
- INAB N/A
- MRKR 44.55
- 52 Week Low
- INAB $1.91
- MRKR $0.81
- 52 Week High
- INAB $12.53
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- INAB 46.89
- MRKR 52.46
- Support Level
- INAB $2.09
- MRKR $0.96
- Resistance Level
- INAB $2.16
- MRKR $1.05
- Average True Range (ATR)
- INAB 0.13
- MRKR 0.05
- MACD
- INAB -0.01
- MRKR 0.00
- Stochastic Oscillator
- INAB 13.11
- MRKR 52.20
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.